Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel-Reference-Cited by-同舟云学术

Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel

Published:2024-02 Issue:2 Volume:85 Page:171-176
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Lara Jr Primo N.,Mayerson Edward,Gertz Erik,Tangen Catherine,Goldkorn Amir,van Loan Marta,Hussain Maha,Gupta Shilpa,Zhang Jingsong,Parikh Mamta,Twardowski Przemyslaw,Quinn David I.,LeBlanc Michael,Vogelzang Nicholas J.,Thompson Ian,Agarwal Neeraj

Publisher

Elsevier BV

Subject

Urology

Reference14 articles.

1. Metabolism in the tumour-bone microenvironment;Whitburn;Curr Osteoporos Rep,2021

2. Adverse effects of androgen deprivation therapy and strategies to mitigate them;Nguyen;Eur Urol,2015

3. Markers of bone metabolism in prostate cancer;Smith;Cancer Treat Rev,2006

4. Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421;Lara;J Natl Cancer Inst,2014

5. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases;Lara;Clin Cancer Res,2006

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide;European Urology Oncology;2024-03

2. Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel;Prostate Cancer and Prostatic Diseases;2024-02-29

3. The Potential of Extracellular Matrix- and Integrin Adhesion Complex-Related Molecules for Prostate Cancer Biomarker Discovery;Biomedicines;2023-12-28

4. Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study;European Urology Oncology;2023-10

5. New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics;Frontiers in Oncology;2023-08-17